Johnson & Johnson (NYSE:JNJ) Shares Sold by West Oak Capital LLC

West Oak Capital LLC lessened its position in Johnson & Johnson (NYSE:JNJ) by 97.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 450 shares of the company’s stock after selling 15,338 shares during the period. West Oak Capital LLC’s holdings in Johnson & Johnson were worth $65,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Bright Futures Wealth Management LLC. raised its stake in shares of Johnson & Johnson by 2.9% during the second quarter. Bright Futures Wealth Management LLC. now owns 3,389 shares of the company’s stock valued at $495,000 after purchasing an additional 94 shares in the last quarter. Sachetta LLC lifted its stake in shares of Johnson & Johnson by 5.6% in the 2nd quarter. Sachetta LLC now owns 6,797 shares of the company’s stock worth $1,097,000 after acquiring an additional 359 shares during the period. Andra AP fonden increased its stake in shares of Johnson & Johnson by 144.0% during the second quarter. Andra AP fonden now owns 461,200 shares of the company’s stock valued at $67,409,000 after acquiring an additional 272,200 shares during the period. Doheny Asset Management CA raised its holdings in Johnson & Johnson by 65.1% during the second quarter. Doheny Asset Management CA now owns 16,327 shares of the company’s stock worth $2,296,000 after purchasing an additional 6,437 shares in the last quarter. Finally, First Interstate Bank lifted its position in Johnson & Johnson by 4.3% in the second quarter. First Interstate Bank now owns 9,260 shares of the company’s stock worth $1,353,000 after purchasing an additional 384 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Bank of America restated a “neutral” rating and set a $166.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, Morgan Stanley raised their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $174.71.

Johnson & Johnson Stock Down 0.1 %

Shares of JNJ traded down $0.20 during mid-day trading on Friday, reaching $142.07. The company’s stock had a trading volume of 8,819,482 shares, compared to its average volume of 8,014,389. The business has a fifty day moving average of $150.03 and a 200 day moving average of $156.04. The company has a market cap of $342.05 billion, a price-to-earnings ratio of 20.56, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the company earned $2.66 EPS. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. As a group, analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.49%. Johnson & Johnson’s dividend payout ratio is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.